[EN] SYNTHESIS AND USE OF THIENOTRIAZOLODIAZEPINES<br/>[FR] SYNTHESE ET UTILISATION DE THIENOTRIAZOLODIAZEPINES
申请人:UNIV LOUISIANA STATE
公开号:WO2001083440A2
公开(公告)日:2001-11-08
A new method to synthesize the platelet-activating factor antagonist which is a derivative of thienotriazolodiazepene, tetrahydro-4, 7, 8, 10 methyl-1(chloro-2 phenyl)-6 (methosy-4 phenyl carbamoyl)-9 pyrido[4,3-:4,5] thieno[3,2-f] triazolo-1,2,4 [4,3-α] diazepine-1,4] (1) is disclosed. The compound synethesized by this new method has been designated 'LAU-8080' which has the same structure as the compound currently named in the literature as 'BN-50730.' LAU-8080 was shown to prevent photoreceptor cell death, inhibit pathological neovascularization in the retina, and minimize the loss of neurons due to ischemic-reperfusion damage due to stroke. Thus LAU-8080 can be used to treat the retinal diseases of age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy. It can also be used to minimize the neuronal damage due to stroke.
本文披露了一种合成血小板活化因子拮抗剂的新方法,该拮抗剂是一种噻唑三氮杂环并恶唑衍生物,化学式为四氢-4,7,8,10-甲基-1(氯-2-苯基)-6-(甲氧基-4-苯基羰酰基)-9-吡啶[4,3-:4,5]-噻唑[3,2-f]三氮杂环-1,2,4[4,3-α]恶唑啉-1,4](1)。用这种新方法合成的化合物被指定为“LAU-8080”,其结构与当前文献中命名为“BN-50730”的化合物相同。研究表明,LAU-8080能够预防光感受器细胞死亡,抑制视网膜中的病理性新生血管形成,并减少因缺血再灌注损伤引起的神经元损失。因此,LAU-8080可用于治疗与年龄相关的黄斑变性、色素性视网膜炎和糖尿病性视网膜病变等视网膜疾病。它也可以用于减少因中风引起的神经元损伤。